Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19
Objective. Cytokine release syndrome (CRS) is a dangerous complication of the new coronavirus infection (COVID-19). The study aimed to compare sarilumab (SAR group) with tocilizumab (TOC group) and patients without anticytokine treatment (CON group) in treatment of CRS in COVID-19.Methods. The retro...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2023-12-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/676 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823860030574690304 |
|---|---|
| author | V. T. Ivashkin R. V. Maslennikov E. V. Vasilieva M. L. Chipurik P. A. Semikova V. V. Semenets T. A. Russkova |
| author_facet | V. T. Ivashkin R. V. Maslennikov E. V. Vasilieva M. L. Chipurik P. A. Semikova V. V. Semenets T. A. Russkova |
| author_sort | V. T. Ivashkin |
| collection | DOAJ |
| description | Objective. Cytokine release syndrome (CRS) is a dangerous complication of the new coronavirus infection (COVID-19). The study aimed to compare sarilumab (SAR group) with tocilizumab (TOC group) and patients without anticytokine treatment (CON group) in treatment of CRS in COVID-19.Methods. The retrospective real life study included COVID-19 patients with C-reactive protein(CRP) level >60 mg/l.Results. We enrolled 24 patients in SAR group, 27 patients in TOC group and 47 patients in CON group. Mortality was lower in SAR and TOC groups than in CON group (12.5% and 14.8% vs. 31.9%; p=0.021 and p=0.031) with no difference between SAR and TOC groups (p=0.389). SAR patients unlike TOC patients required intensive care unit admission less frequently then CON patients (16.7% and 25.9% vs. 46.3%; p=0.013 and p=0.077). An increase in oxygen saturation was observed in SAR and TOC groups (p=0.001 and p=0.004; greater in SAR group [p=0.022]), but not in CON group (p=0.764) in 7-10 days after administration of these drugs. The decrease in CRP level was greater in SAR and TOC groups than in CON group (p=0.016 and p<0.011), with no difference between SAR and TOC groups (p=0.236).Conclusion. Sarilumab is not inferior to tocilizumab in COVID-19 |
| format | Article |
| id | doaj-art-1596e4d0681a4639955eb64d26e77009 |
| institution | Kabale University |
| issn | 1382-4376 2658-6673 |
| language | Russian |
| publishDate | 2023-12-01 |
| publisher | Gastro LLC |
| record_format | Article |
| series | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| spelling | doaj-art-1596e4d0681a4639955eb64d26e770092025-02-10T16:14:38ZrusGastro LLCРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии1382-43762658-66732023-12-01335546410.22416/1382-4376-2023-33-5-54-64573Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19V. T. Ivashkin0R. V. Maslennikov1E. V. Vasilieva2M. L. Chipurik3P. A. Semikova4V. V. Semenets5T. A. Russkova6I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)I.M. Sechenov First Moscow State Medical University (Sechenov University)Objective. Cytokine release syndrome (CRS) is a dangerous complication of the new coronavirus infection (COVID-19). The study aimed to compare sarilumab (SAR group) with tocilizumab (TOC group) and patients without anticytokine treatment (CON group) in treatment of CRS in COVID-19.Methods. The retrospective real life study included COVID-19 patients with C-reactive protein(CRP) level >60 mg/l.Results. We enrolled 24 patients in SAR group, 27 patients in TOC group and 47 patients in CON group. Mortality was lower in SAR and TOC groups than in CON group (12.5% and 14.8% vs. 31.9%; p=0.021 and p=0.031) with no difference between SAR and TOC groups (p=0.389). SAR patients unlike TOC patients required intensive care unit admission less frequently then CON patients (16.7% and 25.9% vs. 46.3%; p=0.013 and p=0.077). An increase in oxygen saturation was observed in SAR and TOC groups (p=0.001 and p=0.004; greater in SAR group [p=0.022]), but not in CON group (p=0.764) in 7-10 days after administration of these drugs. The decrease in CRP level was greater in SAR and TOC groups than in CON group (p=0.016 and p<0.011), with no difference between SAR and TOC groups (p=0.236).Conclusion. Sarilumab is not inferior to tocilizumab in COVID-19https://www.gastro-j.ru/jour/article/view/676coronaviruscytokine release syndromeinterleukin-6tocilizumabsarilumab |
| spellingShingle | V. T. Ivashkin R. V. Maslennikov E. V. Vasilieva M. L. Chipurik P. A. Semikova V. V. Semenets T. A. Russkova Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19 Российский журнал гастроэнтерологии, гепатологии, колопроктологии coronavirus cytokine release syndrome interleukin-6 tocilizumab sarilumab |
| title | Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19 |
| title_full | Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19 |
| title_fullStr | Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19 |
| title_full_unstemmed | Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19 |
| title_short | Sarilumab is not Inferior to Tocilizumab in the Treatment of Cytokine Release Syndrome in COVID-19 |
| title_sort | sarilumab is not inferior to tocilizumab in the treatment of cytokine release syndrome in covid 19 |
| topic | coronavirus cytokine release syndrome interleukin-6 tocilizumab sarilumab |
| url | https://www.gastro-j.ru/jour/article/view/676 |
| work_keys_str_mv | AT vtivashkin sarilumabisnotinferiortotocilizumabinthetreatmentofcytokinereleasesyndromeincovid19 AT rvmaslennikov sarilumabisnotinferiortotocilizumabinthetreatmentofcytokinereleasesyndromeincovid19 AT evvasilieva sarilumabisnotinferiortotocilizumabinthetreatmentofcytokinereleasesyndromeincovid19 AT mlchipurik sarilumabisnotinferiortotocilizumabinthetreatmentofcytokinereleasesyndromeincovid19 AT pasemikova sarilumabisnotinferiortotocilizumabinthetreatmentofcytokinereleasesyndromeincovid19 AT vvsemenets sarilumabisnotinferiortotocilizumabinthetreatmentofcytokinereleasesyndromeincovid19 AT tarusskova sarilumabisnotinferiortotocilizumabinthetreatmentofcytokinereleasesyndromeincovid19 |